View Older Stories View More Recent Stories

Jan 11, 2023 09:00AM AIRSUPRA™ (PT027) approved in the US for asthma
Dec 19, 2022 08:19AM Tesla, Moderna, Mesa Air rise premarket; Meta Platforms lower
Dec 13, 2022 10:02AM AstraZeneca Awards $4M to Nonprofit Organizations to Advance Health Equity
Dec 8, 2022 08:35AM Camizestrant Significantly Delayed Disease Progression in Advanced ER-Positive Breast Cancer, Adding at Least 3.5 Months Benefit Versus FASLODEX® (fulvestrant)
Dec 8, 2022 08:34AM AstraZeneca (AZN) Announces Capivasertib Plus FASLODEX Reduced the Risk of Disease Progression or Death by 40% Versus FASLODEX in Advanced HR-Positive Breast Cancer
Dec 8, 2022 08:30AM Capivasertib Plus FASLODEX® (fulvestrant) Reduced the Risk of Disease Progression or Death by 40% Versus FASLODEX in Advanced HR-Positive Breast Cancer
Dec 7, 2022 08:36AM AstraZeneca (AZN) Announces ENHERTU Achieved Statistically Significant OS, Reducing the Risk of Death by 36% Vs. Trastuzumab Emtansine in Patients With HER2-positive Metastatic Breast cancer in DESTIN
Dec 7, 2022 08:30AM ENHERTU® (fam-trastuzumab deruxtecan-nxki) Achieved Statistically Significant Overall Survival, Reducing the Risk of Death by 36% Vs. Trastuzumab Emtansine (T-DM1) in Patients With HER2-positive Meta
Nov 30, 2022 07:00AM AstraZeneca Showcases Strength of Hematology Portfolio and Pipeline Across Multiple Hard-to-Treat Conditions at ASH 2022
Nov 29, 2022 01:30PM Resilience to Establish a Biomanufacturing Partnership with AstraZeneca and Purchase AstraZeneca’s Manufacturing Site in West Chester, Ohio
Nov 22, 2022 07:05AM AstraZeneca Aims to Redefine Breast Cancer Care With New Data Across the Treatment Spectrum At SABCS 2022
Nov 16, 2022 08:23AM Alexion, AstraZeneca Rare Disease, Completes Acquisition of LogicBio® Therapeutics
Nov 11, 2022 07:38AM IMFINZI and IMJUDO with chemotherapy approved in the US for patients with metastatic non-small cell lung cancer
Nov 10, 2022 11:23AM AstraZeneca EVUSHELD Named on TIME’s List of the Best Inventions of 2022
Nov 10, 2022 08:33AM Viatris Inc (VTRS) Wins Court Decision Invalidating AstraZeneca's (AZN) Symbicort Patent
Nov 9, 2022 07:00AM PT027 Recommended by FDA Advisory Committee as New Rescue Treatment for Asthma
Oct 27, 2022 07:00AM ULTOMIRIS® (ravulizumab-cwvz) showed zero relapses in adults with neuromyelitis optica spectrum disorder (NMOSD) with median treatment duration of 73 weeks
Oct 26, 2022 07:05AM Camizestrant Significantly Improved Progression-free Survival Vs. FASLODEX® (fulvestrant) in SERENA-2 Phase II Trial in Advanced ER-positive Breast Cancer
Oct 26, 2022 07:00AM Capivasertib plus FASLODEX® (fulvestrant) significantly improved progression-free survival vs. FASLODEX in CAPItello-291 Phase III trial in advanced HR-positive breast cancer
Oct 24, 2022 07:12AM AstraZeneca (AZN) Announces IMJUDO in Combination With IMFINZI Approved in US for Patients With Unresectable Liver Cancer
Oct 24, 2022 07:12AM IMJUDO® (tremelimumab) in Combination With IMFINZI® (durvalumab) Approved in the US for Patients With Unresectable Liver Cancer
Oct 20, 2022 09:00AM AstraZeneca Announces Winners of Fourth Annual Cancer Community Awards
Oct 18, 2022 07:33AM Ikena Oncology (IKNA) Provides Research & Development Update on IK-930 Program Targeting the Hippo Pathway
Oct 18, 2022 07:30AM Ikena Oncology Provides Research & Development Update on IK-930 Program Targeting the Hippo Pathway
Oct 12, 2022 07:00AM Alexion aims to advance NMOSD treatment landscape with exceptional ULTOMIRIS® (ravulizumab-cwvz) efficacy data at ECTRIMS 2022
Oct 11, 2022 09:16AM Illumina (ILMN) Enters Strategic Research Collaboration with AstraZeneca (AZN) to Accelerate Drug Target Discovery
Oct 3, 2022 07:15AM Alexion, AstraZeneca Rare Disease to Acquire LogicBio® Therapeutics to Accelerate Growth in Genomic Medicine
Oct 3, 2022 07:01AM LogicBio Therapeutics (LOGC) Acquired by AstraZeneca (AZN) for $2.07/sh
Sep 16, 2022 07:12AM AstraZeneca (AZN) Announces Danicopan Add-On to ULTOMIRIS or SOLIRIS Met Primary Endpoint in ALPHA Phase III Trial for Patients with Paroxysmal Nocturnal Hemoglobinuria
Sep 16, 2022 07:10AM Danicopan (ALXN2040) Add-On to ULTOMIRIS® (ravulizumab-cwvz) or SOLIRIS® (eculizumab) Met Primary Endpoint in ALPHA Phase III Trial for Patients with Paroxysmal Nocturnal Hemoglobinuria Who Experien
Sep 15, 2022 12:00PM AstraZeneca Partners with Jeff Bridges, Kumail Nanjiani, and Emily V. Gordon to Educate the Immunocompromised Community about Added Protection Against COVID-19
Sep 12, 2022 11:06AM AstraZeneca's (AZN) IMFINZI Plus Chemotherapy Improved Overall Survival Benefit in TOPAZ-1 Phase III Trial
Sep 12, 2022 11:05AM IMFINZI® (durvalumab) plus chemotherapy further improved overall survival benefit in advanced biliary tract cancer in the TOPAZ-1 Phase III trial, reducing the risk of death by 24% in additional foll
Sep 12, 2022 05:41AM AstraZeneca (AZN) Reports TAGRISSO Demonstrated 5.5-Year Median DFS in EGFR-mutated Lung Cancer
Sep 12, 2022 05:40AM AstraZeneca (AZN) Reports IMFINZI and tremelimumab with Chemotherapy Nearly Double Sustained Survival Benefit in NSCLC
Sep 12, 2022 05:40AM AstraZeneca (AZN) Reports New Strong ENHERTU Data from DESTINY-Lung02 Phase II Trial
Sep 11, 2022 09:35AM ENHERTU® (fam-trastuzumab deruxtecan-nxki) Continues to Demonstrate Clinically Meaningful Tumor Response in Patients with HER2-mutant Metastatic Non-small Cell Lung Cancer
Sep 11, 2022 08:05AM IMFINZI® (durvalumab) and tremelimumab with chemotherapy demonstrated sustained survival benefit in metastatic non-small cell lung cancer, nearly doubling the number of patients alive after three yea
Sep 11, 2022 08:00AM TAGRISSO® (osimertinib) demonstrated 5.5-year median disease-free survival in the adjuvant treatment of patients with EGFR-mutated lung cancer
Sep 9, 2022 08:00AM LYNPARZA® (olaparib) in Combination with Bevacizumab, and as a Monotherapy, Demonstrates Clinically Meaningful Survival Benefit in 1st-Line Advanced Ovarian Cancer Across Two Phase III Trials
Sep 5, 2022 07:00AM IMFINZI® (durvalumab) Plus Chemotherapy Approved in the US as the First Immunotherapy Regimen for Patients with Advanced Biliary Tract Cancer
Aug 27, 2022 10:59AM New data show FARXIGA significantly lowers the risk of cardiovascular death in patients with heart failure
Aug 27, 2022 10:36AM FARXIGA significantly reduced the risk of cardiovascular death or worsening of heart failure in patients with mildly reduced or preserved ejection fraction in DELIVER Phase III trial
Aug 25, 2022 06:46AM Merck (MRK) and AstraZeneca (AZN) Announces LYNPARZA Approved in Japan as Adjuvant Treatment for Patients With BRCA-Mutated, HER2-Negative High Recurrent Risk Breast Cancer
Aug 24, 2022 07:00AM AstraZeneca aims to transform cancer outcomes with new data across industry-leading portfolio at ESMO 2022
Aug 16, 2022 07:00AM LYNPARZA® (olaparib) in combination with abiraterone granted Priority Review in the US for patients with metastatic castration-resistant prostate cancer
Aug 12, 2022 07:06AM AstraZeneca (AZN), Daiichi Sankyo's ENHERTU approved in US as first HER2-directed therapy for patients with previously treated HER2-mutant metastatic NSCLC
Aug 12, 2022 07:00AM ENHERTU® (fam-trastuzumab deruxtecan-nxki) approved in the US as the first HER2-directed therapy for patients with previously treated HER2-mutant metastatic non-small cell lung cancer
Aug 8, 2022 07:00AM TAGRISSO® plus savolitinib demonstrated 49% objective response rate in lung cancer patients with high levels of MET overexpression and/or amplification in SAVANNAH Phase II trial
Aug 8, 2022 06:01AM HUTCHMED and AstraZeneca Announce that TAGRISSO® Plus Savolitinib Demonstrated 49% Objective Response Rate in Lung Cancer Patients with High Levels of MET Overexpression and/or Amplification in
View More Recent Stories View Older Stories